Thoracic surgery for ovarian cancer recurrence

Aim. Safety, efficiency and diagnostic value of diagnostic and curative thoracic surgical interventions were the objectives of current research dedicated to patients with recurrent ovarian cancer. Materials and Methods. Retrospective analysis of medical records of patients with recurrent ovarian...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	V.V. Boyko, K.V. Kharchenko, R.I. Vereshchako, G.O. Vakulenko
Formato:	article
Lenguaje:	EN UK
Publicado:	Danylo Halytsky Lviv National Medical University 2017
Materias:	ovarian cancer, recurrence, surgery, secondary cytoreduction, organs of the chest cavity Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/8edf138aba70428fa838fdb298765a89
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8edf138aba70428fa838fdb298765a89
record_format	dspace
spelling	oai:doaj.org-article:8edf138aba70428fa838fdb298765a892021-11-10T19:50:04ZThoracic surgery for ovarian cancer recurrence1029-42442415-330310.25040/aml2017.03.031https://doaj.org/article/8edf138aba70428fa838fdb298765a892017-08-01T00:00:00Zhttps://amljournal.com/index.php/journal/article/view/148https://doaj.org/toc/1029-4244https://doaj.org/toc/2415-3303Aim. Safety, efficiency and diagnostic value of diagnostic and curative thoracic surgical interventions were the objectives of current research dedicated to patients with recurrent ovarian cancer. Materials and Methods. Retrospective analysis of medical records of patients with recurrent ovarian cancer, on whom surgical interventions were performed at the State Establishment "Zaitsev V.T. Institute of General and Emergency Surgery of the Academy of Medical Sciences of Ukraine" during January 2010 - December 2015. Recurrence localization was limited by the organs of the thoracic cavity. Both diagnostic and cytoreductive surgical interventions were taken into account. Results and Discussion. Forty three patients met the search criteria. In 11 cases (26%) more than one thoracic localization was diagnosed. Thoracoscopy (n=36; 84%) allows to assess the state of parietal and visceral pleura, to perform the dissection of pleural conjunctions, to determine the extension of pleural involvement and to take a biopsy from its surface. Possibility and feasibility of partial pleverectomy was established thoracoscopically (n=7, 16%). Pleurodesis (n=16; 37%) was performed in order to stop malignant recurrent pleural effusion. Pleurodesis effectiveness: complete remission (n=11; 69%); partial remission (n=4; 25%); progression of the disease (n=1; 6%). Mediastinoscopy was performed in 18 patients (42%) with radiological signs of mediastinal lymphadenopathy. In 12 cases (28%) cancer etiology had been confirmed and further lymphadenectomy was performed. In other cases (n=6; 14%), lymphadenopathy was not malignant with no subsequent surgery. Surgeries for lung parenchyma were the following: atypical lung resection (n=17, 40%), segmentectomy (n=3, 7%), lobectomy (n=2, 5%). Postoperative complications and mortality were 9% (n=4) and 2% (n=1), respectively. Median overall survival for patients with the duration of recurrence-free period <12 months was 9 months, 12-24 months - 21 months, >24 months - 48 months (p<0.05). Isolated parenchymal or lymph nodes lesions were characterized by the most favorable prognosis. The median overall survival rate for lung parenchyma recurrence was 39 months, lymph nodes - 31 months, pleura - 13 months, with more than one localization - 8 months (p<0.05). Conclusions. Recurrent ovarian cancer with of thoracic organs, traditionally, is not considered from the perspective of surgical treatment. Diagnostic surgical interventions allow individualizing treatment. Secondary cytoreduction procedures are safe and do not affect the timing of adjuvant treatment. They are characterized by a positive effect on overall and recurrence-free survival, compared to chemotherapy treatment. The duration of the recurrence-free period affects the median survival after secondary cytoreduction. Isolated lung parenchyma lesion is characterized by the most favorable prognosis. Taking into account the high frequency of the chest cavity lesions in patients with ovarian cancer recurrence, not only the palliative care, but also the development of indications for cytoreductive surgery remains important, as a way to prolong survival.V.V. BoykoK.V. KharchenkoR.I. VereshchakoG.O. VakulenkoDanylo Halytsky Lviv National Medical Universityarticleovarian cancer, recurrence, surgery, secondary cytoreduction, organs of the chest cavityMedicine (General)R5-920ENUKActa Medica Leopoliensia, Vol 23, Iss 3, Pp 31-38 (2017)
institution	DOAJ
collection	DOAJ
language	EN UK
topic	ovarian cancer, recurrence, surgery, secondary cytoreduction, organs of the chest cavity Medicine (General) R5-920
spellingShingle	ovarian cancer, recurrence, surgery, secondary cytoreduction, organs of the chest cavity Medicine (General) R5-920 V.V. Boyko K.V. Kharchenko R.I. Vereshchako G.O. Vakulenko Thoracic surgery for ovarian cancer recurrence
description	Aim. Safety, efficiency and diagnostic value of diagnostic and curative thoracic surgical interventions were the objectives of current research dedicated to patients with recurrent ovarian cancer. Materials and Methods. Retrospective analysis of medical records of patients with recurrent ovarian cancer, on whom surgical interventions were performed at the State Establishment "Zaitsev V.T. Institute of General and Emergency Surgery of the Academy of Medical Sciences of Ukraine" during January 2010 - December 2015. Recurrence localization was limited by the organs of the thoracic cavity. Both diagnostic and cytoreductive surgical interventions were taken into account. Results and Discussion. Forty three patients met the search criteria. In 11 cases (26%) more than one thoracic localization was diagnosed. Thoracoscopy (n=36; 84%) allows to assess the state of parietal and visceral pleura, to perform the dissection of pleural conjunctions, to determine the extension of pleural involvement and to take a biopsy from its surface. Possibility and feasibility of partial pleverectomy was established thoracoscopically (n=7, 16%). Pleurodesis (n=16; 37%) was performed in order to stop malignant recurrent pleural effusion. Pleurodesis effectiveness: complete remission (n=11; 69%); partial remission (n=4; 25%); progression of the disease (n=1; 6%). Mediastinoscopy was performed in 18 patients (42%) with radiological signs of mediastinal lymphadenopathy. In 12 cases (28%) cancer etiology had been confirmed and further lymphadenectomy was performed. In other cases (n=6; 14%), lymphadenopathy was not malignant with no subsequent surgery. Surgeries for lung parenchyma were the following: atypical lung resection (n=17, 40%), segmentectomy (n=3, 7%), lobectomy (n=2, 5%). Postoperative complications and mortality were 9% (n=4) and 2% (n=1), respectively. Median overall survival for patients with the duration of recurrence-free period <12 months was 9 months, 12-24 months - 21 months, >24 months - 48 months (p<0.05). Isolated parenchymal or lymph nodes lesions were characterized by the most favorable prognosis. The median overall survival rate for lung parenchyma recurrence was 39 months, lymph nodes - 31 months, pleura - 13 months, with more than one localization - 8 months (p<0.05). Conclusions. Recurrent ovarian cancer with of thoracic organs, traditionally, is not considered from the perspective of surgical treatment. Diagnostic surgical interventions allow individualizing treatment. Secondary cytoreduction procedures are safe and do not affect the timing of adjuvant treatment. They are characterized by a positive effect on overall and recurrence-free survival, compared to chemotherapy treatment. The duration of the recurrence-free period affects the median survival after secondary cytoreduction. Isolated lung parenchyma lesion is characterized by the most favorable prognosis. Taking into account the high frequency of the chest cavity lesions in patients with ovarian cancer recurrence, not only the palliative care, but also the development of indications for cytoreductive surgery remains important, as a way to prolong survival.
format	article
author	V.V. Boyko K.V. Kharchenko R.I. Vereshchako G.O. Vakulenko
author_facet	V.V. Boyko K.V. Kharchenko R.I. Vereshchako G.O. Vakulenko
author_sort	V.V. Boyko
title	Thoracic surgery for ovarian cancer recurrence
title_short	Thoracic surgery for ovarian cancer recurrence
title_full	Thoracic surgery for ovarian cancer recurrence
title_fullStr	Thoracic surgery for ovarian cancer recurrence
title_full_unstemmed	Thoracic surgery for ovarian cancer recurrence
title_sort	thoracic surgery for ovarian cancer recurrence
publisher	Danylo Halytsky Lviv National Medical University
publishDate	2017
url	https://doaj.org/article/8edf138aba70428fa838fdb298765a89
work_keys_str_mv	AT vvboyko thoracicsurgeryforovariancancerrecurrence AT kvkharchenko thoracicsurgeryforovariancancerrecurrence AT rivereshchako thoracicsurgeryforovariancancerrecurrence AT govakulenko thoracicsurgeryforovariancancerrecurrence
_version_	1718439695961030656

Thoracic surgery for ovarian cancer recurrence

Ejemplares similares